早产儿接种GSK六联疫苗(DTPa-HBV-IPV/Hib)的安全性与免疫原性综述
本文汇总10项临床研究和15年上市后安全性监测数据,评估GSK六联疫苗(DTPa-HBV-IPV/Hib)在早产/低出生体重儿中单独或与其他儿童疫苗联合接种的安全性和免疫原性。结果显示,完成3剂基础免疫后至少92.5%的早产/低出生体重儿对所有疫苗抗原血清阳性,加强免疫应答稳健;乙肝和Hib血清阳性率及抗体浓度似乎低于足月儿;13%-30%医学稳定的早产儿接种后出现呼吸暂停,多发生在第1剂后,大多自行缓解或仅需 minimal 干预。结论认为该疫苗在早产/低出生体重儿中安全性和免疫原性临床可接受,但需在极早产和极低出生体重儿中进一步研究。
要点
- 早产/低出生体重儿按实际年龄接种GSK六联疫苗,3剂基础免疫后至少92.5%血清阳性。
- 乙肝和Hib血清阳性率及抗体浓度似乎低于足月儿。
- 13%-30%医学稳定早产儿接种后出现呼吸暂停,多在第1剂后,大多自行缓解。
核心结论
- GSK六联疫苗单独或与其他儿童疫苗联合用于早产/低出生体重儿基础及加强免疫,安全性和免疫原性临床可接受。
- 极早产和极低出生体重儿需进一步研究。
- 现有数据支持按实际年龄为早产/低出生体重儿接种GSK六联疫苗。
研究设计与样本
- 综述汇总10项临床研究和15年上市后安全性监测数据。
- 评估GSK六联疫苗单独或与肺炎球菌结合疫苗、轮状病毒疫苗、脑膜炎球菌疫苗及呼吸道合胞病毒IgG联合接种。
- 对象为有早产/低出生体重史的婴儿。
主要发现
- 临床研究中,胎龄小至24周的早产/低出生体重儿完成3剂基础免疫后,至少92.5%对所有疫苗抗原血清阳性。
- 加强免疫后免疫应答稳健。
- 乙肝和Hib的血清阳性率及抗体浓度在早产/低出生体重儿中似乎低于足月儿。
- 13%-30%医学稳定的早产儿接种后出现呼吸暂停,通常在第1剂后。
- 接种后心肺事件的发生似乎受基础新生儿疾病严重程度影响,大多数事件自行缓解或仅需 minimal 干预。
临床怎么用
- 现有数据支持按实际年龄为有早产/低出生体重史的婴儿接种GSK六联疫苗进行基础及加强免疫。
- 极早产和极低出生体重儿需进一步研究。
局限性
- 需在极早产和极低出生体重儿中进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infants with history of prematurity (<37 weeks gestation) and low birth weight (LBW, <2500 g) are at high risk of infection due to functional immaturity of normal physical and immunological defense mechanisms. Despite current recommendations that infants with history of prematurity/LBW should receive routine immunization according to the same schedule and chronological age as full-term infants, immunization is often delayed. METHODS: Here we summarize 10 clinical studies and 15 years of post-marketing safety surveillance of GSK's hexavalent vaccine (DTPa-HBV-IPV/Hib), a combined diphtheria-tetanus-acellular-pertussis-hepatitis-B-inactivated-poliovirus-Haemophilus influenzae-type-b (Hib) conjugate vaccine, when administered alone, or co-administered with pneumococcal conjugate, rotavirus, and meningococcal vaccines and respiratory syncytial virus IgG to infants with history of prematurity/LBW in clinical trials. RESULTS: At least 92.5% of infants with history of prematurity/LBW as young as 24 weeks gestation in clinical studies were seropositive to all vaccine antigens after 3-dose primary vaccination with GSK's hexavalent DTPa-HBV-IPV/Hib vaccine, with robust immune responses to booster vaccination. Seropositivity rates and antibody concentrations to hepatitis B and Hib appeared lower in infants with history of prematurity/LBW than term infants. Between 13-30% of medically stable infants with history of prematurity developed apnea after vaccination with GSK's hexavalent DTPa-HBV-IPV/Hib vaccine; usually after dose 1. The occurrence of post-immunization cardiorespiratory events appears to be influenced by the severity of any underlying neonatal condition. Most cardiorespiratory events resolve spontaneously or require minimal intervention. GSK's hexavalent DTPa-HBV-IPV/Hib vaccine was well tolerated in co-administration regimens. CONCLUSION: GSK's hexavalent DTPa-HBV-IPV/Hib vaccine alone or co-administered with other pediatric vaccines has a clinically acceptable safety and immunogenicity profile when used in infants with history of prematurity/LBW for primary and booster vaccination. Additional studies are needed in very premature and very LBW infants. However, currently available data support using GSK's hexavalent DTPa-HBV-IPV/Hib vaccine to immunize infants with history of prematurity/LBW according to chronological age.
引用
- Omeñaca F, Vázquez L, Garcia-Corbeira P, et al. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. Vaccine. 2018. PMID: 29336924. doi:10.1016/j.vaccine.2018.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。